Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts. Atossa has initiated a Phase 2 clinical study using its microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer.
Oral endoxifen is the Company's second development program. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer.
Atossa Genetics is passionate about improving breast health and the overall well-being and health of women and men.
|Size (employees)||18 (est)|
Net income (Q2, 2018)
EBIT (Q2, 2018)
Market capitalization (14-Dec-2018)
Closing stock price (14-Dec-2018)
|USD||Q3, 2013||Q1, 2014||Q2, 2014||Q3, 2014||Q2, 2015||Q3, 2015||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2018|
Depreciation and Amortization
Atossa Genetics has 1.04k Twitter Followers. The number of followers has decreased 0.8% month over month and decreased 1.6% quarter over quarter
When was Atossa Genetics founded?
Atossa Genetics was founded in 2009.
Who are Atossa Genetics key executives?
Atossa Genetics's key executives are Steven C. Quay, Kyle Guse and Janet Rose Rea.
How many employees does Atossa Genetics have?
Atossa Genetics has 18 employees.
Who are Atossa Genetics competitors?
Competitors of Atossa Genetics include Galectin Therapeutics, Stemline Therapeutics and Cellular Biomedicine Group.
Where is Atossa Genetics headquarters?
Atossa Genetics headquarters is located at 4105 E Madison St, Seattle.
Where are Atossa Genetics offices?
Atossa Genetics has an office in Seattle.
How many offices does Atossa Genetics have?
Atossa Genetics has 1 office.